Medtronic CoreValve Gains New Indication For Higher Risk Sufferers

Medtronic’s CoreValve technique nowadays acquired a second indication from the FDA for use in individuals with significant aortic stenosis who are at substantial threat for surgical procedure. The transcatheter aortic valve substitute (TAVR) system was at first accredited earlier this yr for use in patients who were  too ill or frail for conventional open heart surgery.

The new approval is based mostly on outcomes from the US CoreValve Higher-Risk Study published in the New England Journal of Medicine. In the trial, 795 individuals with significant aortic stenosis who who had been at high risk for surgical procedure had been randomized to surgical aortic valve substitute (SAVR) or  CoreValve. At one yr the charge of death was 14.two% in the TAVR group versus 19.one% in the SAVR group, a variation that was very important for noninferiority (P&lt0.001) and even reached significance for superiority (P=.04).

Medtronic stated that the FDA had approved the complete CoreValve platform (23mm, 26mm, 29mm and 31mm size valves) – all of which are delivered by means of the smallest commercially obtainable TAVR delivery technique.

“This rigorous trial has defined a new regular for transcatheter valve functionality, with superiority results that give doctors even far more self-confidence in producing TAVR therapy selections,” mentioned David Adams, co-principal investigator of the trial, in a Medtronic press release. “With this approval, we can deal with more sufferers due to the broad selection of CoreValve sizes, and we have an choice compared to surgical treatment that gives a greater possibility for a longer life even though minimizing the risk of stroke.”

After a relatively slow commence the TAVR marketplace now seems poised for higher group. In addition to the new CoreValve indication, Edwards’ 2nd generation TAVR program is anticipated to obtain approval quickly. Additional, the current settlement of a seemingly countless series of patent disputes between Medtronic and Edwards should let the firms to target on healthcare troubles without having worrying about legal threats.

Medtronic CoreValve Gains New Indication For Higher Risk Sufferers

Boehringer Ingelheim"s Oral Anticoagulant Gains New Indication

The new oral anticoagulants carry on to achieve extra indications from the FDA. Earlier these days Boehringer Ingelheim announced that the FDA had accredited Pradaxa (dabigatran) for the treatment of venous thromboembolism (VTE), which includes each deep venous thrombosis (DVT) and pulmonary embolism (PE).

Last month Bristol-Myers Squibb’s and Pfizer’s Eliquis (apixaban) gained an indication for VTE prophylaxis following hip or knee substitute surgical procedure. Johnson &amp Johnson’s Xareleto (rivaroxaban) had presently received this indication. Hence, all 3 of the new oral anticoagulants have now received FDA approval for the main indications of stroke prevention in patients with nonvalvular atrial fibrillation (SPAF), DVT prophylaxis following hip or knee substitute surgical procedure, and treatment method of folks who have or have had VTE.

1 significant variation in the VTE treatment labels is that both Eliquis and Xarelto have been studied using a single-drug approach. These medication are authorized for acute use in the hospital and for continued use afterwards. By contrast, Pradaxa was studied in individuals after they had received parenteral anticoagulants and is indicated for use following therapy with a parenteral anticoagulant for five to 10 days. It can also be utilised in individuals who have been previously treated for VTE.

“Venous thromboembolism is the third most typical cardiovascular disease soon after myocardial infarction and stroke. About one-third of patients with a DVT or PE will suffer a recurrence inside of 10 years,” stated Samuel Z. Goldhaber, in a Boehringer Ingelheim press release. “Dabigatran has established efficacy and security for stroke danger reduction in individuals with non-valvular atrial fibrillation. This new FDA approval expands dabigatran’s indications to consist of therapy and the reduction of the chance of recurrence of DVT and PE.”

The new indication is based mostly on outcomes from four global Phase III scientific studies evaluating the efficacy and safety of Pradaxa in the therapy of DVT and PE: RE-COVER, RE-COVER II, RE-MEDYSM, and RE-SONATE.

Boehringer Ingelheim"s Oral Anticoagulant Gains New Indication

FDA Grants New Indication For Pfizer/Bristol Anticoagulant

The FDA has authorized a new indication for apixaban (Eliquis), the anticoagulant drug produced by Bristol-Myers Squibb Bristol-Myers Squibb and Pfizer Pfizer. The new indication is for the prophylaxis of deep vein thrombosis (DVT) in individuals who have undergone hip or knee replacement surgery. DVT can lead to the lifestyle-threatening condition of pulmonary embolism (PE). The DVT prophylaxis indication joins the previously approved indication of stroke prevention in sufferers who have nonvalvular atrial fibrillation.

In accordance to the organizations, approximately 719,000 total knee substitute surgeries and 332,000 hip replacement surgeries are performed each and every year in the US. The use of anticoagulants are suggested in these patients simply because they are at elevated danger for developing DVT and PE.

The new indication is based mostly on results of the ADVANCE clinical trial program in which apixaban was compared to enoxaparin in far more than 11,000 individuals.

Between the new oral anticoagulants only rivaroxaban (Xarelto, Johnson &amp Johnson Johnson &amp Johnson) had been authorized previously for DVT prophylaxis in orthopedic patients.

FDA Grants New Indication For Pfizer/Bristol Anticoagulant

FDA Once Yet again Rejects New Indication For Johnson & Johnson"s Xarelto

The third time wasn’t the charm. The FDA these days turned turned down– for the third time– the supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto, Johnson &amp Johnson Johnson &amp Johnson) for use in acute coronary syndrome individuals to lessen MI, stroke or death. In addition, the FDA– for the second time– turned down the sNDA for rivaroxaban in the same population for the reduction of stent thrombosis.

The complete response letters come as minor shock, considering that an FDA advisory panel final month strongly recommended against approval for the indications. As I’ve reported right here on several occasions, the huge sum of missing data from the pivotal ATLAS ACS 2-TIMI 51 trial has been the source of the company’s inability to acquire the ACS indications. Though J&ampJ has produced significant efforts to fill in the missing data, the FDA reviewers and panel members did not think the information was reliable sufficient to attain firm conclusions about the relative safety and efficacy of rivaroxaban for use in ACS.

“We remain committed to delivering sufferers who have suffered from acute coronary syndrome with additional safety towards stent thrombosis and secondary lifestyle-threatening cardiovascular occasions,” mentioned a J&ampJ executive in a statement. “We are evaluating the contents of the letters and will establish the acceptable up coming actions.”

FDA Rescinds Xarelto REMS

In a separate improvement, the FDA has rescinded the Xarelto REMS (Risk Evalaution and Mitigation Technique). The company had been required to communicate the risks of an increased threat of thrombotic events when the drug was discontinued without having an ample alternative anticoagulant and of decreased efficacy when not taken with the evening meal.

FDA Once Yet again Rejects New Indication For Johnson & Johnson"s Xarelto

FDA Panel After Once more Rejects New Indication For J&J Drug

(Photograph credit: Wikipedia)

The FDA’s Cardiovascular and Renal Drugs Advisory Committee once once again turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson &amp Johnson’s Xarelto (rivaroxaban). The virtually unanimous vote (10-, with one abstention) was in line with a hugely adverse overview from FDA workers members.

Although originally the topic of higher praise when it initial came out, the pivotal ATLAS ACS two-TIMI 51 trial has been bedeviled by criticism because the FDA drew consideration to the unusually massive sum of missing trial information. Previous discussions of the trial at the FDA brought the word “missingness” into widespread utilization in the health-related local community. Although J&ampJ made efforts to supply some of the missing data this time around, in the end the panel members agreed with the most latest assessment from the FDA reviewers that the huge quantity of still-missing data made it unattainable to reach firm conclusions about the relative security and efficacy of the drug in the setting of ACS.

Panel member Linda Fried, from the University of Pittsburgh, gave voice to a view adopted by many of the committee members. ATLAS, she mentioned, was most likely “an all round optimistic study” but, since of the big sum of missing information and the absence of a confirmatory research, was “not robust enough” to support the ACS indication. Speaking on behalf of the sponsor, cardiologists C. Michael Gibson and Marvin Konstam attempted to persuade the panel to accept their numerous constructive analyses of the trial. But panel members, such as outspoken critics like Steve Nissen and Sanjay Kaul, left small doubt all through the day’s meeting that they have been unlikely to vote in favor of the new indication.

“We enjoy the thoroughness of the committee’s evaluation and proceed to feel rivaroxaban, in addition to the recent normal of care, might aid provide sufferers with ACS further safety against lifestyle-threatening cardiovascular occasions this kind of as death, heart assault and stroke. We will operate with the FDA to tackle questions raised nowadays,” mentioned J&ampJ’s Paul Burton, in a statement.

FDA Panel After Once more Rejects New Indication For J&J Drug